Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objectives: New data suggest that glioma stem-like cells (GSCs) and neural stem/progenitor cells (NSCs) may share common origins. GSCs drive tumor proliferation and appear to be resistant to classic chemotherapy, while the effects of chemotherapy on NSCs are not well studied. As the role of NSCs in learning and memory is increasingly recognized, we need to identify drugs that reduce neurotoxicity but are still effective against glial tumors.
Methods: We treated 3 human NSC cultures and multiple low- and high-grade GSC cultures with the commonly used agents temozolomide (TMZ) and cisplatin (CIS), and with 2 newer, promising drugs: the proteasome inhibitor bortezomib (BTZ) and the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (ERL). We measured cell survival, proliferation, cell death induction, and drug resistance markers.
Results: TMZ decreased NSC viability, while minimally affecting GSCs. TMZ induced NSC death, which was partially compensated for by increased proliferation. CIS had similar effects. The NSC's sensitivity to TMZ and CIS correlated with low expression of the multidrug resistance gene ABCG2, but not of MGMT or MSH1/MLH2. BTZ caused an 80%decrease in GSCs, while minimally affecting NSCs. GSCs had lower proteasome levels and activity after BTZ treatment. ERL treatment also decreased GSC numbers, but not NSC viability, which correlated with low EGFR expression in NSCs compared to GSCs.
Conclusions: Newer chemotherapy agents ERL and BTZ are effective against GSCs yet produce minimal effects on NSCs, while the older drugs TMZ and CIS are more toxic for NSCs than for GSCs. The identification and testing of more selective drugs is clearly warranted.
Footnotes
Study funding: Supported in part by start-up funds to D. Bota from the University of California, Irvine, and by Children's Hospital of Orange County through the National Human Neural Stem Cell Resource.
-
- BTZ
- bortezomib
- CIS
- cisplatin
- ERL
- erlotinib
- GSC
- glioma stem-like cell
- MGMT
- methyl-guanine methyl transferase
- NSC
- neural stem/progenitor cell
- TMZ
- temozolomide
-
Editorial, page 1118
-
Supplemental data at www.neurology.org
- Received May 20, 2010.
- Accepted October 15, 2010.
- Copyright © 2011 by AAN Enterprises, Inc.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
- Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy
- Marc C Chamberlain, Provider, University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliancechambemc@u.washington.edu
Submitted August 08, 2011 - Reply from the Authors
- Daniela A. Bota, Assistant Professor of Neurology, UC Irvine Medical Center, Irvine, CAdbota@uci.edu
- Mark E. Linskey, Philip H. Schwartz
Submitted August 08, 2011
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Dennis Bourdette and Dr. Lindsey Wooliscroft
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Article
Limited role for extended maintenance temozolomide for newly diagnosed glioblastomaDorothee Gramatzki, Philipp Kickingereder, Bettina Hentschel et al.Neurology, March 15, 2017 -
Articles
Safety and feasibility of long-term temozolomide treatment in patients with high-grade gliomaP. Hau, D. Koch, T. Hundsberger et al.Neurology, February 26, 2007 -
Articles
Temozolomide for low-grade gliomasPredictive impact of 1p/19q loss on response and outcomeG. Kaloshi, A. Benouaich-Amiel, F. Diakite et al.Neurology, May 21, 2007 -
Patient Page
Fighting brain tumors while protecting the brainThe stem cell storyDavid Spencer et al.Neurology, March 28, 2011